NEKTAR THERAPEUTICS news, videos and press releases - Page 2
For more news please use our advanced search feature.
NEKTAR THERAPEUTICS - More news...
NEKTAR THERAPEUTICS - More news...
- Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
- Nektar Therapeutics Reports Third Quarter 2023 Financial Results
- Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
- Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
- Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
- Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
- Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
- Nektar Therapeutics Reports Second Quarter 2023 Financial Results
- Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
- Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
- Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
- Nektar Therapeutics Reports First Quarter 2023 Financial Results
- Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
- Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
- Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
- Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
- Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)
- Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
- Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
- Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
- Nektar Therapeutics to Host Investor & Analyst Event on December 12th
- Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
- Nektar Therapeutics Reports Third Quarter 2022 Financial Results
- Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets
- Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
- Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
- Norges Bank - Form 8.3 - Nektar Therapeutics, Inc
- Form 8.3 - The Vanguard Group, Inc.: Nektar Therapeutics, Inc
